Children with COVID-19 show different immune responses, but better outcomes than adults

September 21, 2020

A comparison of children and adults hospitalized with COVID-19 reveals pediatric patients, who had better outcomes and shorter hospital stays, displayed altered immune responses and more limited production of antibodies against infection. While these preliminary findings are descriptive and do not establish a causative relationship, the study hints that these immune differences could help explain why children have consistently developed less severe cases of COVID-19 than adults during the pandemic. COVID-19 has caused more than 29 million cases and 929,000 deaths globally, and high hospitalization rates from the disease have overwhelmed healthcare systems in many cities. Clinicians have noted that children and young people have milder symptoms and rarely progress to life-threatening respiratory complications - the opposite of what has been observed with other viral infections such as respiratory syncytial virus. However, the basis for these clinical differences has been unclear. Carl Pierce and colleagues compared data from 65 children and youths (under 24 years of age) and 60 adults hospitalized with COVID-19 in metropolitan New York. The infected children - including some who had the emerging complication known as multisystem inflammatory syndrome - were less likely to require mechanical ventilation (8% vs 37%) and had lower mortality (3% vs 28%) than the adults. However, adults showed higher antibody production and T cell responses to the viral spike protein, but lower amounts of inflammatory molecules like IL-17A and IFNγ that are involved in innate immunity. "The results provide new insights into potential mechanisms that may contribute to age-related differences in disease resolution ... and may have implications for ongoing efforts with convalescent plasma and the development of therapeutic antibodies," Pierce et al. write.

American Association for the Advancement of Science

Related Antibodies Articles from Brightsurf:

Scientist develops new way to test for COVID-19 antibodies
New research details how a cell-free test rapidly detects COVID-19 neutralizing antibodies and could aid in vaccine testing and drug discovery efforts.

Mussels connect antibodies to treat cancer
POSTECH research team develops innovative local anticancer immunotherapy technology using mussel protein.

For an effective COVID vaccine, look beyond antibodies to T-cells
Most vaccine developers are aiming solely for a robust antibody response against the SARS-CoV-2 virus, despite evidence that antibodies are not the body's primary protective response to infection by coronaviruses, says Marc Hellerstein of UC Berkeley.

Children can have COVID-19 antibodies and virus in their system simultaneously
With many questions remaining around how children spread COVID-19, Children's National Hospital researchers set out to improve the understanding of how long it takes pediatric patients with the virus to clear it from their systems, and at what point they start to make antibodies that work against the coronavirus.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

Re-engineering antibodies for COVID-19
Catholic University of America researcher uses 'in silico' analysis to fast-track passive immunity

Seroprevalence of antibodies to SARS-CoV-2 in 10 US sites
This study estimates how common SARS-CoV-2 antibodies are in convenience samples from 10 geographic sites in the United States.

Neutralizing antibodies in the battle against COVID-19
An important line of defense against SARS-CoV-2 is the formation of neutralizing antibodies.

Three new studies identify neutralizing antibodies against SARS-CoV-2
A trio of papers describes several newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV infection.

More effective human antibodies possible with chicken cells
Antibodies for potential use as medicines can be made rapidly in chicken cells grown in laboratories.

Read More: Antibodies News and Antibodies Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to